- /
- Supported exchanges
- / US
- / TXG.NASDAQ
10X Genomics Inc (TXG NASDAQ) stock market data APIs
10X Genomics Inc Financial Data Overview
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with 10X Genomics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get 10X Genomics Inc data using free add-ons & libraries
Get 10X Genomics Inc Fundamental Data
10X Genomics Inc Fundamental data includes:
- Net Revenue: 639 M
- EBITDA: -30 669 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-06
- EPS/Forecast: -0.284
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
10X Genomics Inc News
New
Torex Gold Resources' (TSE:TXG) Earnings Are Of Questionable Quality
Unsurprisingly, Torex Gold Resources Inc.'s (TSE:TXG) stock price was strong on the back of its healthy earnings report. However, we think that shareholders may be missing some concerning details in t...
1 Cash-Producing Stock on Our Watchlist and 2 We Question
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luckily for you, we built StockStory to hel...
United Natural Foods Stock Is Up 85%. One Investor Just Sold Out Completely
On May 12, 2026, Quantedge Capital disclosed in a Securities and Exchange Commission filing that it sold out of United Natural Foods(NYSE:UNFI), liquidating about 88,000 shares in a trade estimated at...
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year
On May 12, 2026, Quantedge Capital disclosed in an SEC filing that it sold out its entire stake in Supernus Pharmaceuticals(NASDAQ:SUPN) during the first quarter, with an estimated transaction value o...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.